MiRNA-21 inhibition enhances RANTES and IP-10 release in MCF-7 via PIAS3 and STAT3 signalling and causes increased lymphocyte migration

Biochemical and Biophysical Research Communications

Volumn 439, Issue 3, 2013, Pages 384-389

  Wang, Zhiyu ^a,b   Han, Jinxiang ^a,b   Cui, Yazhou ^b   Zhou, Xiaoyan ^a,b   Fan, Kaixi ^c  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING HOSPITAL   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Cancer immunotherapy; Chemokine; Immunoresistance; MicroRNA; PIAS3; STAT3

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; MICRORNA 21; PIAS3 PROTEIN; PROTEIN INHIBITOR OF ACTIVATED STAT; RANTES; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LYMPHOCYTE MIGRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CANCER IMMUNOTHERAPY; CHEMOKINE; IMMUNORESISTANCE; MICRORNA; PIAS3; STAT3;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL5; CHEMOKINE CXCL10; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTES; MICRORNAS; MOLECULAR CHAPERONES; PROTEIN INHIBITORS OF ACTIVATED STAT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84884593828     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.072     Document Type: Article

References (33)

1. Antonia S., Mulé J.J., Weber J.S. Current developments of immunotherapy in the clinic. Curr. Opin. Immunol. 2004, 16:130-136.
2. Gajewski T.F., Louahed J., Brichard V.G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010, 16:399-403.
3. Sharma P., Shen Y., Wen S., et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl. Acad. Sci. USA 2007, 104:3967-3972.
4. Monteagudo C., Martin J.M., Jorda E., et al. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathologic prognostic factors. J. Clin. Pathol. 2007, 60:596-599.
5. Harlin H., Meng Y., Peterson A.C., et al. Chemokine expression in melanoma metastases associated with CD8+ T cell recruitment. Cancer Res. 2009, 69:3077-3085.
6. Messina J.L., Yu H., Riker A.I., et al. Activated stat-3 in melanoma. Cancer Control 2008, 15:196-201.
7. Massi D., Tarantini F., Franchi A., et al. Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod. Pathol. 2006, 19:246-254.
8. Larue L., Delmas V. The WNT/Beta-catenin pathway in melanoma. Front Biosci. 2006, 11:733-742.
9. Guo H., Samarakoon A., Vanhaesebroeck B., Malarkannan S. The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. J. Exp. Med. 2008, 205:2419-2435.
10. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
11. Perry M.M., Moschos S.A., Williams A.E., et al. Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J. Immunol. 2008, 180:5689-5698.
12. Perry M.M., Williams A.E., Tsitsiou E., et al. Divergent intracellular pathways regulate interleukin-1beta-induced miR-146a and miR-146b expression and chemokine release in human alveolar epithelial cells. FEBS Lett. 2009, 583:3349-3355.
13. Tili E., Michaille J.J., Cimino A., et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 2007, 179:5082-5089.
14. Yao Q., Xu H., Zhang Q.Q., et al. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem. Biophys. Res. Commun. 2009, 388:539-542.
15. Gabriely G., Wurdinger T., Kesari S., et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell Biol. 2008, 28:5369-5380.
16. Wang P., Zou F., Zhang X. MicroRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 2009, 69:8157-8165.
17. Li T., Li D., Sha J., et al. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem. Biophys. Res. Commun. 2009, 383:280-285.
18. Ren Y., Zhou X., Mei M., et al. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010, 10:27.
19. Gao W., Xu J., Liu L., et al. A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed. Pharmacother. 2012, 66:21-28.
20. Xiong Q., Zhong Q., Zhang J., et al. Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics. J. Proteome Res. 2012, 11:2078-2090.
21. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
22. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7:41-51.
23. Wang T., Niu G., Kortylewski M., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10:48-54.
24. -δδCt method. Methods 2001, 25:402-408.
25. Zhang H.Y., Sun H. Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Lett. 2010, 287:91-97.
26. Wu Z., Lu H., Sheng J., et al. Inductive microRNA-21 impairs anti-mycobacterial responses by targeting IL-12 and Bcl-2. FEBS Lett. 2012, 586:2459-2467.
27. Rot A., von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 2004, 22:891.
28. Campbell D.J., Kim C.H., Butcher E.C. Chemokines in the systemic organization of immunity. Immunol. Rev. 2003, 195:58.
29. Sabatel C., Malvaux L., Bovy N., et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS ONE 2011, 6:e16979.
30. Schramedei K., Mörbt N., Pfeifer G., et al. MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene 2011, 30:2975-2985.
31. Yang C.H., Yue J., Fan M., et al. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res. 2010, 70:8108-8116.
32. Wang Z.Y., Han J.X., Cui Y.Z., et al. Circulating microRNA-21 as noninvasive predictive biomarker for response in cancer immunotherapy. Med. Hypotheses 2013, 81:41-43.
33. Bader A.G., Brown D., Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70:7027-7030.